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Switzerland; and 4Department of Radiology, University Hospital Lausanne (CHUV), Lausanne, SwitzerlandRenal tissue hypoxia is a ﬁnal pathway in the development
and progression of chronic kidney disease (CKD), but
whether renal oxygenation predicts renal function decline
in humans has not been proven. Therefore, we performed a
prospective study and measured renal tissue oxygenation
by blood oxygenation level-dependent magnetic
resonance imaging (BOLD-MRI) in 112 patients with CKD,
47 with hypertension without CKD, and 24 healthy control
individuals. Images were analyzed with the twelve-layer
concentric objects method that divided the renal
parenchyma in 12 layers of equal thickness and reports the
mean R2* value of each layer (a high R2* corresponds to
low oxygenation), along with the change in R2* between
layers called the R2* slope. Serum creatinine values were
collected to calculate the yearly change in estimated
glomerular function rate (MDRD eGFR). Follow up was three
years. The change in eGFR in CKD, hypertensive and control
individuals was -2.0, 0.5 and -0.2 ml/min/1.73m2/year,
respectively. In multivariable regression analysis adjusted
for age, sex, diabetes, RAS-blockers, eGFR, and proteinuria
the yearly eGFR change correlated negatively with baseline
24 hour proteinuria and the mean R2* value of the cortical
layers, and positively with the R2* slope, but not with the
other covariates. Patients with CKD and high outer R2* or a
ﬂat R2* slope were three times more likely to develop an
adverse renal outcome (renal replacement therapy or over
a 30% increase in serum creatinine). Thus, low cortical
oxygenation is an independent predictor of renal function
decline. This ﬁnding should stimulate studies exploring the
therapeutic impact of improving renal oxygenation on
renal disease progression.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).C hronic kidney disease (CKD) is a major public healthproblem.1 Diabetes, arterial hypertension (AH), andproteinuria are well-known risk factors for disease
progression, but predicting the evolution of CKD remains
a difﬁcult task. For incompletely understood reasons, the
glomerular ﬁltration rate (GFR) of some CKD patients
will hardly decrease over the years, whereas in others, it
will rapidly progress toward end-stage renal disease. The
early identiﬁcation of CKD patients at risk of progressive
renal function decline (progressors) would allow a more
focused distribution of health care resources and
improved planning of renal replacement methods. How-
ever, a multitude of circulating or urinary biomarkers has
been proposed to predict outcome, so far with inconsis-
tent results.2
Renal tissue hypoxia is considered as the common ﬁnal
pathway in the development and progression of CKD, irre-
spective of its cause.3 Animal studies have provided evidence
of this hypothesis, yet data in humans were limited for a long
time due to the lack of a method to assess renal tissue
oxygenation noninvasively in humans. This situation has
changed thanks to the development of blood oxygenation
level–dependent magnetic resonance imaging (BOLD-MRI).4
In brief, BOLD-MRI uses the paramagnetic properties of
deoxyhemoglobin to assess tissue oxygenation: the higher the
local deoxyhemoglobin levels are, the higher the so-called
apparent relaxation rate R2* (s1) is and the lower local
tissue oxygen content is, assuming that blood pO2 is in
equilibrium with tissue pO2. BOLD-MRI is performed
without contrast and therefore is an ideal method for patients
with CKD. Standardization of the examinations and re-
ﬁnements in the methods to analyze the images has resulted
in a reproducible technique with low interobserver
variability.5
Recent BOLD-MRI studies have demonstrated that the
R2* values of renal parenchyma are higher in CKD patients,Kidney International (2018) 93, 932–940
Table 1 | Baseline characteristics of CKD patients,
hypertensive patients, and normotensive controls
Characteristics CKD AH Control PANOVA
N 112 47 24
Age (yr) 56  14 56  11 47  11 0.008
Sex (% female) 31.9 35 48 0.21
Diabetes (%) 25.0 16.7 0 0.004
Hypertension (%) 79.8 100 0 <0.001
Creatinine (mmol/l) 151  89 75  13 72  15 <0.001
eGFR (ml/min per 1.73 m2) 55  29 90  15 97  14 <0.001
Body mass index (kg/m2) 28  5 28  5 26  5 0.3
Systolic BP (mm Hg) 135  19 142  16 121  14 <0.001
Diastolic BP (mm Hg) 77  12 82  10 74  11 0.0048
Urinary 24-hr volume (l) 2.2  0.8 1.9  0.7 2.1  1.2 0.18
Urinary 24-hr sodium (mmol) 167  88 164  84 153  79 0.57
Hemoglobin (g/dl) 130  18 137  13 135  11 0.05
Hematocrit (%) 38  5 40  3 40  3 0.04
Glycemia (mmol/l) 6.6  2.3 6.2  1.3 5.4  1.1 0.04
Concomitant medications
RAS blockers (%) 62.6 38.6 0 <0.001
Calcium antagonists (%) 29.8 33.9 0 <0.001
Beta-blockers (%) 28.1 37.5 0 <0.001
Diuretics (%) 22.6 19.6 0 <0.001
Statins (%) 49 32 6.3 <0.001
AH, arterial hypertension; ANOVA, analysis of variance; BP, blood pressure; CKD,
chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; RAS, renin-
angiotensin system.
Table 2 | Radiologic and arterial parameters according to
group
Parameters CKD AH Control PANOVA
N 112 47 24
Magnetic resonance
imaging
Outer R2* (s1)a 21.2  3.1 20.6  1.7 20.4  2.5 0.04
Inner R2* (s1)b 24.2  2.6 24.4  1.8 24.6  2.1 0.68
R2* slope
(hertz per % depth)
7.2  2.8 8.7  3.0 9.4  3.0 <0.001
Delta inner R2* (s1)c 2.2  1.2 3.0  1.4 3.2  1.1 <0.001
Ultrasound
Renal length (mm) 108.3  12.6 114.9  12.2 113.8  8.7 0.002
Renal resistive index 0.71  0.09 0.67  0.07 0.64  0.04 <0.001
Pulse wave analysis
PWV car-fem (m/s) 9.5  2.7 10.2  2.9 7.9  1.3 <0.001
AH, arterial hypertension; ANOVA, analysis of variance; car-fem; carotid-femoral; CKD,
chronic kidney disease; PWV, pulse wave velocity.
aOuter R2*: mean R2* of the 3 most superﬁcial, cortical layers of renal parenchyma.
bInner R2*: mean R2* of the 8th to 10th layer (corresponding to medulla) of renal
parenchyma.
cDelta inner R2* represents the change in R2* of the inner layers 15 minutes after i.v.
furosemide.
M Pruijm et al.: Reduced cortical oxygenation predicts renal function decline in humans c l i n i ca l i nves t iga t ionsuggesting lower renal tissue oxygenation.6–8 Differences in
R2* between CKD patients and healthy controls have been
mainly reported in the cortex, whereas medullary oxygenation
seems relatively well preserved at a lower GFR.
Acute decreases in medullary R2* levels have been
described after the administration of furosemide and are
greater in young persons with preserved renal function
compared with older persons or patients with CKD.9,10 The
effect of furosemide has been explained by the fact that it
blocks the Naþ-Kþ-2Cl transporter in the thick ascending
loop of Henle, will acutely decrease oxygen-consuming active
sodium transport, and increase local pO2.
11 BOLD-MRI
combined with i.v. furosemide is therefore considered by
many as a functional test: the greater the change is in R2*, the
more functional tubuli that are still present.12
To the best of our knowledge, the reported BOLD-MRI
studies were all cross-sectional or short-term interventional
studies, and it remains therefore unknown whether renal
tissue hypoxia (high baseline R2* values) or furosemide-
induced changes in R2* predict renal function decline in
humans. The aim of this study was therefore to assess whether
renal tissue oxygenation as measured with BOLD-MRI is
associated with renal function decline in a cohort of CKD
patients, hypertensive patients without CKD, and normo-
tensive controls.
RESULTS
A baseline visit was performed in 226 participants (120 CKD
patients, 62 hypertensive patients, and 44 healthy controls).
Fifteen participants were excluded due to the inability to
undergo BOLD-MRI (unexpected claustrophobia or other
contraindication for MRI). Seven patients were excluded
because of insufﬁcient image quality. A total of 10 hyper-
tensive patients and 11 controls did not want to return for a
follow-up visit and were therefore also excluded. Baseline
characteristics of the remaining 183 participants are shown in
Table 1. In the CKD group, 28 patients had diabetic ne-
phropathy, 33 had hypertensive nephropathy, and 21 had
glomerulonephritis. Details of the measured radiological and
arterial parameters are shown in Table 2. An example of
BOLD-MRI of a healthy volunteer and a CKD patient is
shown in Figure 1 (see Methods section for details). More
detailed information on other causes of CKD, baseline esti-
mated GFR (eGFR), and BOLD-MRI results according to the
underlying cause of CKD are provided in Supplementary
Table S1.
The follow-up period (mean  SD) for all participants was
3.0  1.1 years (3.2  1.2 for CKD, 2.7  1.0 for AH, and 2.7
 0.7 for controls). On average, 5.3  2.7 creatinine values
were available per individual (6.6  2.6 for CKD, 3.7 1.7 for
AH, and 2.9  0.7 for controls).
The yearly eGFR change was, respectively, 2.0  6.0, 0.5
 4.9, and 0.2  5.3 ml/min per 1.73 m2 per year in CKD,
hypertensive patients, and controls (PANOVA¼ 0.027); the
evolution of the eGFR over time per group is shown graph-
ically in Supplementary Figure S1.Kidney International (2018) 93, 932–940Results of uni- and multivariable regression analysis
including all participants, with yearly eGFR change as a
dependent (outcome) variable and age, sex, group, diabetes,
renin-angiotensin system blockers, baseline eGFR, and pro-
teinuria as independent variables, are shown in Table 3. In
fully adjusted models, the yearly change in eGFR correlated
negatively with baseline 24-hour proteinuria (regression co-
efﬁcient b  SE per gram of proteinuria: 1.49  0.60, P ¼
0.012) and mean R2* value of the outer (cortical) layers (b/
second1: 0.44  0.16, P ¼ 0.009), but not with the other933
Figure 1 | Example of BOLD-MRI according to the TLCO technique. Images obtained in a healthy volunteer (a–c) and in a chronic kidney
disease (CKD) patient (d–f). The outer border and inner border of the renal parenchyma are drawn manually on anatomic templates; regarding
the inner borders, sections deeper than the pyramids were not included to avoid the inclusion of large vascular structures and calices (a,d);
corresponding R2* maps are shown (b,e). After importation in Matlab, the selected kidney parenchyma was divided into 12 layers of equal
thickness. Voxels with R2* <10 or >50 s1 or voxels with badly exponentially ﬁtted signal were suppressed (c,f). The graphs on the right are the
corresponding R2* proﬁles and summarize the mean R2* of each of the 12 layers, averaged from the 4 coronal sections; the higher R2* is, the
lower oxygenation is (see text for details). The percentage scale refers to the relative depth of each layer. The R2* slope (the red line) is ﬂatter in
the CKD patient (f) than the healthy control (c). BOLD-MRI, blood oxygenation level–dependent magnetic resonance imaging; TLCO, 12-layer
concentric objects. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
Table 3 | Multivariable analysis including all participants showing the associations between the yearly change in eGFR
(outcome variable) and clinical variables
Clinical variables Age- and sex-adjusted b (95% CI) P Fully adjusted b (95% CI)a P
Age (per year) 0.007 (0.07 to 0.056) 0.83 0.027 (0.06 to 0.11) 0.56
Sex (female vs. male) 0.59 (2.34 to 1.17) 0.51 1.23 (3.21 to 0.76) 0.22
Diabetes (yes vs. no) 0.80 (2.96 to 1.35) 0.47 0.27 (2.23 to 2.78) 0.83
Baseline eGFR (ml/min per 1.73m2) 0.057 (0.03–0.09) <0.001 0.013 (0.030 to 0.057) 0.55
Proteinuria (per g/24 h) 2.32 (3.0 to 1.62) <0.001 1.49 (2.65 to 0.33) 0.012
RAS blocker (yes vs. no) 1.05 (2.77 to 0.68) 0.23 0.32 (1.63 to 2.27) 0.75
Outer R2* (per s1) 0.34 (0.69 to 0.007) 0.045 0.44 (0.76 to 0.11) 0.009
Delta Inner R2* (per s1) 0.67 (0.05 to 1.38) 0.068 0.19 (0.69 to 1.07) 0.67
Inner R2* (per s1) 0.11 (0.30 to 0.53) 0.6 0.34 (0.78 to 0.097) 0.126
R2* slope (per hertz per % depth) 0.48 (0.17–0.78) 0.002 0.45 (0.11–0.80) 0.010
Renal resistive index (per 0.1) 1.37 (2.54 to 0.19) 0.022 0.23 (1.63 to 1.17) 0.75
PWV (per m/s) 1.67 (5.98 to 2.67) 0.45 0.25 (0.16 to 0.66) 0.23
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; PWV, pulse wave velocity;
RAS, renin-angiotensin system.
aAdjusted for age, sex, diabetes, baseline eGFR, proteinuria, and use of RAS blockers.
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Table 4 | Characteristics of CKD patients according to their
R2* value of the outer layers (above or below the 90th
percentile)
Characteristics
R2* <90th
percentile
R2* ‡90th
percentile Pa
N 100 12
Age (yr) 56.5  13 57  18 0.9
Sex (% women) 32.5 25 0.6
Proteinuria (g/24 hr) 0.89  1.52 0.81  1.22 0.87
Diabetes (yes vs. no) 28.9 16.7 0.37
Baseline eGFR
(ml/min per 1.73 m2)
56.2  29 49.4  26 0.46
Yearly change in eGFR
(ml/min per 1.73 m2)
0.8  5.8 3.9  6.6 0.008
Baseline creatinine
(per mmol/l)
153  97 169  97 0.6
RAS blocker (yes vs. no) 47.4 58.3 0.48
Outer R2* (sec1) 20.3  1.6 26.6  4.6 <0.001
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; RAS, renin-
angiotensin system.
R2* values above the 90th percentile correspond to the lowest cortical oxygenation.
aThe P values were obtained with c2 tests for categorical variables and Wilcoxon’s
rank sum tests for numerical variables.
M Pruijm et al.: Reduced cortical oxygenation predicts renal function decline in humans c l i n i ca l i nves t iga t ionmentioned covariates. Hence, the higher cortical R2* is
(corresponding to lower oxygenation), the larger the decline
in yearly eGFR is. In addition, the yearly change in eGFR
correlated positively with the R2* slope (b, 0.45  0.17,
P ¼ 0.010); hence, the ﬂatter the slope, the larger the decline
in eGFR. No correlations were found between the
furosemide-induced change in medullary R2* (delta inner
R2*) and yearly eGFR change.
Similar results were found when the CKD group was
analyzed separately: in fully adjusted models, the yearly
change in eGFR was associated with 24-hour proteinuria (b 
SE per gram of proteinuria 1.29  0.58, P ¼ 0.029), the
outer R2* (b  SE per s1: 0.31  0.21, P ¼ 0.015), and the
R2* slope (b 0.66  0.25, P ¼ 0.01), whereas the inner
(medullary) R2*, delta inner R2*, age, sex, baseline eGFR,
diabetes status, and use of renin-angiotensin system blockers
were not (Supplementary Table S2).
The percentage of progressors (eGFR decline >3 ml/min
per 1.73 m2 per year) in CKD patients, hypertensive pa-
tients, and controls was, respectively, 30.2%, 18.2%, and
16.7%. Progressors had higher outer R2* values (21.3  2.6
vs. 20.2  1.9 s1, P ¼ 0.033) and ﬂatter slopes (7.3  2.8
vs. 8.2  2.9 Hz per percentage of depth, P ¼ 0.038) than
nonprogressors. In multivariable logistic regression,
progressor status was associated with proteinuria (odds
ratio per gram: 2.87 (95% conﬁdence interval [CI] 1.44–
5.73, P ¼ 0.003), outer R2* (OR per s1: 1.20 [1.03–
1.40], P ¼ 0.019), and R2* slope (OR per unit 0.91 [95% CI
0.81–0.99], P ¼ 0.04), but not with baseline eGFR, age, sex,
diabetes status, use of renin angiotensin system blockers,
inner R2*, or furosemide-induced change in R2*
(Supplementary Table S3).
A total of 5 patients in the CKD group died during follow-
up, 13 had to start dialysis, and 6 had an increase in creatinine
>30%. For patients with AH, these numbers were, respec-
tively, 0, 0, and 3, whereas none of the controls died or
experienced a severe renal adverse event. In 3 of 5 CKD
patients, death occurred after the initiation of dialysis. Two
CKD patients underwent transplantation, in both cases after
the initiation of dialysis.
In 5 of 12 CKD patients with an outer R2* above the 90th
percentile (high R2* group), a major renal adverse event
developed over time versus 14 of 100 patients with an outer
R2* below the 90th percentile, corresponding to a 3 times
higher risk (P ¼ 0.037), a positive predictive value of 42%,
and a negative predictive value of 86%. Baseline character-
istics according to R2* group are shown in Table 4. The
results of the Kaplan-Meier analysis according to outer R2*
percentile are shown in Figure 2. CKD patients from the
high R2* group remained signiﬁcantly less often free of a
major renal event over time compared with the low R2*
group (log-rank test, P ¼ 0.0031). Similar results were found
for the extremes of the R2* slope: in 9 of 13 CKD patients
with an R2* slope lower than the 10th percentile, a major
renal event developed compared with 14 of 88 CKD patients
with an R2* slope above the 10th percentile, correspondingKidney International (2018) 93, 932–940to a 4.3 times higher risk (P < 0.001), a positive predictive
value of 69%, and a negative predictive value of 84%. This
was conﬁrmed with the Kaplan-Meier analysis (log-rank test,
P ¼ 0.0009).
Receiver-operating characteristic curves for the variables
that showed the strongest association with the occurrence
of major renal events (proteinuria, outer R2*, and R2*
slope) are shown in Figure 3a. Discrimination obtained
with the variable proteinuria, expressed as the area under
the curve (AUC), was 0.83 (95% CI 0.72–0.94) and slightly
stronger than the AUC of the R2* slope (AUC: 0.80, 95%
CI 0.65–0.96) or outer R2* (AUC: 0.71, 95% CI: 0.52–
0.88). A further increase in the AUC was obtained by
combining the 3 variables (AUC: 0.89, 95% CI 0.75–0.97)
(see Figure 3b).
A total of 68 CKD patients (mean  SD age, 56.7  13.7
years, 46% female) underwent a second MRI at the 1-year
follow-up visit, and 34 underwent a third MRI at the 3-year
follow-up visit. Twenty-two AH patients and 25 healthy
controls underwent a second MRI at the 3-year follow-up
visit. Results of their outer and inner R2* values, R2*
slopes, and furosemide-induced changes according to the
study visit are shown in Supplementary Table S4. There were
no signiﬁcant changes in the R2* values or their slopes be-
tween the baseline and 1- and 3-year study visits. Of note, the
yearly eGFR decline in the CKD patients who underwent
follow-up MRI after 1 year was 1.7  7.7 ml/min per 1.73
m2 and 0.3  2.8 ml/min per 1.73 m2 in the 34 CKD
patients who underwent a follow-up MRI after 3 years. The
outer R2* values of the CKD patients with rapid renal func-
tion decline (>3 ml/min per 1.73 m2 per year, N ¼ 16)
increased slightly over time (from 21.0  2.5 to 21.7  3.2 s1
after 3 years, P ¼ 0.16), whereas no change occurred in the
CKD patients without rapid renal function decline (from 20.6
 2.1 to 20.7  1.7 s1, P ¼ 0.92).935
Figure 2 | Kaplan-Meier curve depicting the proportion of chronic kidney disease (CKD) patients free of major renal events (initiation
of renal replacement therapy or increase in serum creatinine >30%) in CKD patients according to their cortical R2* value over time
(days).
c l i n i ca l i nves t iga t i on M Pruijm et al.: Reduced cortical oxygenation predicts renal function decline in humansDISCUSSION
To the best of our knowledge, this is the ﬁrst report of an
association between renal tissue hypoxia and renal function
decline in humans. Using BOLD-MRI, we indeed show that
the lower the oxygenation of the cortex (corresponding to
high R2* values) is, the faster the yearly decline of the eGFR.
In this study, renal tissue oxygenation was also associated withFigure 3 | (a) Receiver operating characteristic (ROC) curve and area
values (in blue), and the R2* slope (in red) for their prediction of a
variables combined.
936hard renal endpoints. CKD patients with the lowest cortical
oxygenation were 3 times more likely to experience a major
renal event (the need for renal replacement therapy or an
increase of >30% in baseline serum creatinine) than those
with preserved renal tissue oxygenation. The R2* slope, which
depends less on the absolute R2* values but merely on their
intracompartmental distribution, was also strongly associatedunder the curve (AUC) of 24-hour proteinuria (in black), outer R2*
major renal event in CKD patients. (b) ROC curve and AUC of the 3
Kidney International (2018) 93, 932–940
M Pruijm et al.: Reduced cortical oxygenation predicts renal function decline in humans c l i n i ca l i nves t iga t ionwith renal function decline and hard renal endpoints. As
such, a ﬂatter slope corresponded to a greater yearly decline in
renal function and vice versa.
In contrast, we did not ﬁnd any association between the
furosemide-induced change in medullary R2* values as
assessed at baseline and the eGFR decline.
A possible role of renal ischemia as a major determinant of
renal disease progression was ﬁrst proposed by Fine et al.13 in
1998. The so-called chronic hypoxia hypothesis states that
loss of glomeruli leads to loss of peritubular capillaries, which
induces interstitial hypoxia. The latter triggers local inﬂam-
mation and ﬁbrosis, leading to further ischemia and renal
function decline, thus producing a vicious circle. This hy-
pothesis has been supported by many animal studies,14,15 yet
direct evidence in humans was still lacking. The results of this
prospective study using BOLD-MRI to assess renal tissue
oxygenation support the role of chronic tissue hypoxia in
CKD development and progression in humans.
Associations between baseline renal R2* values, eGFR
decline, and adverse renal outcome were conﬁned to the
outer, more cortical layers of the renal parenchyma, and no
association was found between eGFR decline or renal
outcome and baseline R2* values of inner medullary layers.
This is in line with previous BOLD-MRI observations from
our and other groups showing that cortical, but not medul-
lary, oxygenation is decreased in CKD.7,8 The cortical hypoxia
can be explained by the combination of a reduction in cortical
blood ﬂow and intact nephrons, oxygen-dependent glomer-
ular hyperﬁltration in residual nephrons, and reduced meta-
bolic efﬁciency of proximal tubular cells, as encountered in
CKD.16 Proximal tubular cells are the predominant cell type
in the cortex. They are also the most energy-consuming
tubular cells containing a great number of mitochondria
with intense transport activity. Therefore, they are very sus-
ceptible to changes in oxygenation,3 whereas reduction in
renal blood ﬂow mainly occurs at the cortical level in different
forms of CKD.17,18 Although hypothetical, this might explain
why cortical oxygenation has a greater impact on eGFR
decline than medullary oxygenation.
Furosemide blocks active sodium transport in Henle’s
loops and leads to an acute decrease in oxygen consumption
in the medulla. Some authors have suggested that the BOLD-
MRI response to furosemide could be used as a test to assess
residual renal function (the response to furosemide being a
marker of tubular functional reserve) in animals and humans
with ischemic renal disease due, for example, to renal artery
stenosis.13,19 In this study, we also assessed the clinical interest
of measuring renal oxygenation after the administration of
furosemide as a prognostic marker of renal function decline.
Thus, BOLD-MRI was repeated 15 minutes after the
administration of furosemide in all participants, and the
changes in R2* were analyzed in each of the 12 layers. As
expected, furosemide-induced changes in R2* (called Delta
R2*) were greater in deep medullary layers and greater in
healthy controls, as reported previously.10 Changes in R2*-
induced by furosemide were smaller in CKD patients, mostKidney International (2018) 93, 932–940likely due to the fact that they have less functional tubuli per
volume of renal mass but also because the tubular secretion of
furosemide, which is necessary for its activity, is reduced in
CKD. However, we did not ﬁnd any association between the
furosemide-induced change in R2* and eGFR decline or
progressor status, limiting the future application of the
furosemide test as a predictor of renal function decline in
nonstenotic kidneys. Due to the speciﬁc structure of the
kidneys with the columns of Bertin, the inner layers, as
assessed with the 12-layer concentric objects (TLCO) tech-
nique, most likely also contained cortical tissue. This may
have diluted the effect of furosemide and partly explain the
lack of predictive power of the furosemide test.
In contrast, the R2* slope was strongly associated with
eGFR decline and an adverse renal outcome. This is relevant
for clinical practice because it is known that the R2* values
per se are inﬂuenced by MRI-related characteristics,5,20 and
this limits comparisons of measurements among different
centers. The R2* slope possibly overcomes this shortcoming
because it merely depends on the intracompartmental dis-
tribution and less on the absolute R2* values. Additional
multicenter studies are needed to validate this statement and
to assess the usefulness of measuring the R2* slope in a
clinical context.
A subgroup of participants underwent a second or third
MRI, enabling us to assess whether long-term changes in
renal tissue oxygenation do occur. We found that the R2*
values did not change signiﬁcantly over time, although there
was a trend toward higher outer R2* values over time among
CKD patients with a rapid decline in eGFR. The stability of
R2* values over time in hypertensive patients and controls
underlines the reproducibility of BOLD-MRI if performed
under standardized conditions. In addition, this ﬁnding also
illustrates that those with reduced renal tissue oxygenation at
baseline remain hypoxic over long periods of time, which will,
in theory, expose them to the vicious circle, as stated by the
chronic hypoxia hypothesis.
This study must be seen in the perspective of its strengths
and limitations. Among its strength are the monocentric
prospective design, the inclusion of a control group, the use of
a standardized hydration protocol, and a well-validated,
reproducible method of BOLD-MRI analysis. A limitation is
the lack of a histologic “gold standard” to validate BOLD-
MRI, which is inherent to most studies in this ﬁeld. Be-
sides, the TLCO technique cannot differentiate with certainty
cortex from medulla. Yet, even renal biopsy has limitations in
its ability to predict the decline in renal function over time.
Taken together, this study describes for the ﬁrst time as-
sociations between renal tissue oxygenation and eGFR decline
and conﬁrms that renal tissue oxygenation is an important
determinant in CKD progression, thus conﬁrming the
chronic hypoxia hypothesis. This study also opens the road to
further studies exploring functional MRI as a tool to inves-
tigate new therapeutic strategies that may retard renal disease
progression. However, several shortcomings still need to be
addressed. First, BOLD-MRI is not widely available and937
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universally standardized. Third, as illustrated by the receiver-
operating characteristic curve analysis, the ability of
BOLD-MRI to distinguish progressors from nonprogressors
is weaker than proteinuria, which is an easy and inexpensive
approach to assess the renal risk in daily practice. Neverthe-
less, the combination of the classic biomarker proteinuria
with BOLD-MRI parameters increased the AUC. One may,
therefore, expect that the ongoing development of multi-
parametric renal MRI protocols that combine different MRI
techniques such as phase-contrast MRI, arterial spin labeling,
BOLD-MRI, and diffusion-weighted imaging will further
improve our capacity to predict renal outcome while per-
forming only 1 MRI session.7,21 This will eventually lead to a
better and earlier identiﬁcation of CKD patients at the highest
risk of end-stage renal disease.
METHODS
This monocentric research project was approved by the local insti-
tutional review committee (Ethical Committee of the Canton de
Vaud, Switzerland) and conducted according to the principles of the
Declaration of Helsinki. Written informed consent was obtained
from all participants.
Study population
Patients with CKD stages 1 through 4 or with AH without CKD
followed at the outpatient clinic of the Nephrology and Hypertension
Service at the University Hospital of Lausanne (CHUV) were eligible
for this study. CKD was deﬁned as an eGFR#60 ml/min per 1.73 m2
or the presence of albuminuria, irrespective of its cause.22,23 AH was
deﬁned as a mean ofﬁce blood pressure $140/90 mm Hg measured
on more than 1 occasion or an ofﬁce blood pressure <140/90
mm Hg while taking 1 or more antihypertensive drugs. All patients
willing to participate had to be at least 18 years old and able to
understand the study protocol. A healthy control group was also
included. Controls were recruited by local advertisement and were
normotensive, untreated healthy individuals without a history of
kidney disease or other concomitant morbidity and without struc-
tural renal abnormalities on a screening ultrasound scan. Exclusion
criteria for all participants were age <18 years, a contraindication to
MRI such as claustrophobia or the presence of a pacemaker or other
implanted metallic device, or the presence of life-threatening
comorbidities with a short life expectancy. CKD patients could not
participate if they were on renal replacement therapy, had a single
kidney, had autosomal dominant polycystic kidney disease, or acute
kidney injury during the previous 6 months, according to the
KDIGO (Kidney Disease: Improving Global Outcomes) deﬁnition.24
Study protocol
CKD and AH patients had a study visit at baseline, 1 year, and 3 years
after study inclusion. Healthy controls only had a baseline visit and a
3-year study visit. At each follow-up visit, patient records were
reviewed for intercurrent medical events (cardiovascular complica-
tions, hospitalization), and, if necessary, the treating physician was
contacted for further details. Major events (e.g., initiation of renal
replacement therapy, death) were immediately reported to the
principal investigator.
All participants were instructed to perform a 24-hour urine
collection and not to drink alcohol the day before the study visit. All938participants were allowed to eat a light breakfast on the day of the
study visit. Patients continued their regular medication intake.
An identical oral hydration protocol was followed by each
participant at home on the day of the study visit. The study visit was
performed between 11 AM and 2 PM and included a questionnaire, a
complete physical examination, blood and urine sampling, a renal
ultrasound scan, and a BOLD-MRI examination. Blood pressure was
measured 5 times after 10 minutes of rest with an automated Omron
705IToscillometric device, according to the recommendations of the
European Society of Hypertension.25
Serum and urine creatinine values were measured in the central
laboratory of CHUV using the IDMS-traceable Jaffe kinetic
compensated method (Roche Diagnostics, Rotkreuz, Switzerland,
maximum intra- and interbatch CV: 2.9%–0.7%), and the MDRD
(Modiﬁcation of Diet in Renal Disease) formula was used to calculate
the eGFR. All renal ultrasound scans were performed by the same
experienced operator in gray-scale and Doppler mode using the
Aplio XG device (Toshiba Systems, AG/Sa, Volketswil, Switzerland).
The renal resistive indexes were measured on 3 segmental arteries
(superior, middle, and inferior) in each kidney. The values were then
averaged to obtain the mean value for each participant.
BOLD-MRI measurements were carried out on a 3-Twhole-body
MR system (MAGNETOM Trio, Siemens Medical Systems, Erlangen,
Germany), as previously described.8 In brief, 4 coronal slices ob-
tained in expiration were selected from morphologic images for
functional evaluation with BOLD-MRI. Twelve T2*-weighted images
were recorded within a single breath hold of 12.4 s with a modiﬁed
Multi Echo Data Image Combination sequence (MEDIC) with the
following parameters: repetition time (TR), 65 ms; echo time (TE),
6-52.2 ms (equidistant echo time spacing 4.2 ms); ﬂip angle, 30;
ﬁeld of view, 400  400 mm2; voxel size, 0.8  0.8  5 mm3; slice
thickness, 5 mm; slice distance, 5.5 mm; bandwidth, 331 Hz/pixels;
and matrix, 256  256 (interpolated to 512  512). Images were
analyzed with Matlab 7.11 (The MathWorks Inc., Natick, MA). R2*
maps were calculated voxel by voxel using the linear least square ﬁt of
the logarithm of the signal.
The 12-layer concentric objects method (TLCO) was used to
analyze the images, as previously described.8 In each coronal slice,
the circumference of the renal parenchyma was drawn manually on
anatomic templates. Concerning the inner border, care was taken not
to include vascular structures or calyces. Hereafter, an automatic
algorithm divided the selected renal parenchyma in 12 layers of equal
thickness; the R2* values of each layer were combined per kidney
with the voxels present in the same layer of the other 3 coronal slices.
By averaging the R2* values per layer of all 4 coronal slices, the mean
R2* of each layer was obtained for the kidney. (See Figure 1a–c for an
example of a healthy control and Figure 1d–f for a patient with
CKD.) The mean R2* value of the outer 3 layers was used as a proxy
of renal cortical oxygenation (called Outer R2*), whereas the mean
R2* value of the inner 8th to 10th layers was used as a proxy of
medullary oxygenation (called Inner R2*). The mean R2* values of
all 12 layers at increasing depth were plotted as a curve, called the
R2* radial proﬁle. The R2* radial proﬁles were shifted down to the x-
axis, such that the value of the third point was 0 for every curve. This
shift permitted a comparison of the shapes of the curves instead of
their absolutes values. The slope of the linear part of this curve (R2*
slope) was expressed as the change in hertz per percentage of change
of depth and its regression coefﬁcient b was calculated with the
linear least-square regression technique.
The procedure was repeated for all 4 coronal series 15 minutes
after the administration of 0.3 mg/kg of i.v. furosemide.Kidney International (2018) 93, 932–940
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efﬁcient) of the TLCO technique for each layer was between 0.85 and
0.99 for the layers and between 0.78 and 0.80 for the R2* slope,
depending on the CKD stage.8
Statistics
Statistical analysis was performed with STATA 14.0 (StataCorp,
College Station, TX). Quantitative values were expressed as mean
 SD or median values (range). Qualitative variables were
expressed as number (percentage). Normality was assessed with
skewness and kurtosis tests. Analysis of variance, Student t test,
Wilcoxon rank sum test, or c2 test was used as appropriate to
compare clinical characteristics and R2* values of the groups.
Because no signiﬁcant differences were observed between the R2*
values of the right and left kidneys, the mean of both kidneys was
used in all analyses shown.
The rate of change of eGFR slope was based on all available
creatinine-based eGFR values from baseline until the last follow-up
visit. Creatinine values of CKD and AH patients obtained during
routine ambulatory control visits were also included. For partici-
pants who died, underwent transplantation, or initiated dialysis
during follow-up, the creatinine value of the last study visit or
ambulatory visit when the patient was in stable condition was used
to assess the eGFR slope. The steepness of the eGFR slope was
calculated with linear regression analysis. Based on a predeﬁned
power calculation, a minimum of 150 participants had to be
included to have 80% power to detect (a combination of) variants
explaining 2.4% (w1.5 ml/min per 1.73 m2) of GFR variance.
Multivariate linear regression analysis was performed to explore the
associations of clinical and radiologic variables (renal resistive in-
dexes, outer and inner R2*, and furosemide-induced changes in
inner R2* and R2* slope) with the eGFR slope.
We further explored the association of eGFR with clinical and
radiologic variables by stratifying individuals according to a yearly
eGFR decline of less than or greater than 3 ml/min per 1.73 m2
(nonprogressors vs. progressors), according to the deﬁnition used by
the US Food and Drug Administration to indicate a clinically
important decline in kidney function.26 Multivariable logistic
regression, adjusted for age, sex, baseline eGFR, diabetes, use of
renin-angiotensin system blockers, and 24-hour proteinuria, was
used to determine the independent association of the radiologic
variables with progressor status.
Kaplan-Meier analysis was used to assess the proportion of CKD
patients free of major renal events (deﬁned as an increase in serum
creatinine >30% or the need for renal replacement therapy27), ac-
cording to their outer R2* level. Because it was recently demon-
strated that a minority of CKD patients accounts for the higher R2*
values observed in CKD patients,7 those with outer R2* values above
the 90th percentile were compared with CKD patients whose R2*
values were below the 90th percentile threshold in this Kaplan-Meier
analysis. For participants in whom a major renal event did not
develop, data until December 31, 2015 were included and censored
hereafter. The log-rank test was used to compare the proportion free
of renal event in the 2 groups. For all analyses, P < 0.05 was
considered signiﬁcant.
Receiver-operating characteristic curves were built to assess the
discriminative accuracy of different variables to predict major renal
events. The comparison (c-statistic) was performed according to the
nonparametric approach proposed by DeLong et al.28Kidney International (2018) 93, 932–940DISCLOSURE
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Figure S1. The evolution of the estimated glomerular ﬁltration rate
(eGFR) over time in each group. In this ﬁgure, the 95% conﬁdence
intervals are presented as colored areas that overlapped for arterial
hypertension (AH) and control groups. CKD, chronic kidney disease.
Table S1. Detailed information on the underlying causes of chronic
kidney disease (CKD) and their respective baseline estimated
glomerular ﬁltration rate (eGFR), yearly eGFR decline, and blood
oxygenation level–dependent magnetic resonance imaging (BOLD-
MRI) results.
Table S2. Multivariable analysis including participants suffering from
CKD showing the associations between the yearly change in eGFR
(outcome variable) and clinical variables.
Table S3. Multivariable logistic regression analysis showing the
associations between the risk of renal progression (estimated
glomerular ﬁltration rate [eGFR] decline $3 ml/min per 1.73 m2) and
clinical variables, expressed as odds ratio (OR) and corresponding
95% conﬁdence interval (CI).
Table S4. Changes in renal R2* and slope values over time, per
patient category (the mean R2* value of the right and left kidneys is
shown on each occasion).
Supplementary material is linked to the online version of the paper at
www.kidney-international.org
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